CD27 and ovarian cancer: Among our predicted drugs, as the only predicted CD27 agonistic antibody, Varlilumab has been previously used to explore the treatment of a wide range of hematologic and solid tumors, e.g., in early clinical trials, varlilumab demonstrated preliminary efficacy against hematologic and ovarian cancers (65, 66).